Source: Eur Respir J 2016; 47: 1000-1002



Rating:

Share or cite this content

Citations should be made in the following way:
Slaats Michiel H.C., Hoefsloot Wouter, Magis-Escurra Cecile, Boeree Martin J., Wattenberg Melanie, Kuipers Saskia, van Ingen Jakko. Regimens for nontuberculous mycobacterial lung disease lack early bactericidal activity. Eur Respir J 2016; 47: 1000-1002

Member's Comments

No comment yet.

Related content which might interest you: The impact of new ATS/IDSA guideline for nontuberculous mycobacterial disease on the diagnosis of nontuberculous mycobacterial lung disease in Korea Source: Annual Congress 2008 - Aetiology of respiratory infections: mycobacteria and fungi Year: 2008 Serial sputum induction in nontuberculous mycobacterial pulmonary disease Source: Eur Respir J, 55 (6) 1902196; 10.1183/13993003.02196-2019 Year: 2020 When is an infectious disease? The clinical spectrum of nontuberculous mycobacterial pulmonary disease Source: International Congress 2019 – New guidelines for treatment of nontuberculous mycobacterial pulmonary disease Year: 2019 Infection or colonisation: indicators to initiate antimycobacterial treatment in nontuberculous mycobacterial infections Source: Annual Congress 2010 - Advances in the diagnosis of tuberculosis and nontuberculous mycobacterial infections: a joint ERS and ATS symposium Year: 2010 The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease Source: Eur Respir J 2015; 45: 1177-1179 Year: 2015 Non-tuberculous mycobacterial lung disease and COPD Source: Eur Respir Monogr 2015; 69: 172-184 Year: 2015 Management of pulmonary nontuberculous mycobacteria disease Source: Eur Respir Monogr 2018; 81: 222-237 Year: 2018 Evaluating the non-tuberculous mycobacteria effect in the tuberculosis infection diagnosis Source: Eur Respir J 2010; 35: 338-342 Year: 2010 Evaluation of the airway microbiome in nontuberculous mycobacteria disease Source: Eur Respir J, 52 (4) 1800810; 10.1183/13993003.00810-2018 Year: 2018 Different antimycobacterial activity of macrophages in various lung tuberculosis legions of patients Source: Virtual Congress 2020 – Non-tuberculous mycobacteria and latent tuberculosis infection Year: 2020 New guidelines for treatment of nontuberculous mycobacterial pulmonary disease Source: Virtual Congress 2020 – German programme 2020 Year: 2020 Cure rates in nontuberculous mycobacterial pulmonary disease Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 Cardiovascular disease risk in patients with nontuberculous mycobacteria disease treated with macrolide Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017 Treatment of pulmonary NTM infection: can it be done? Source: Annual Congress 2007 - Nontuberculous mycobacteria (NTM): a slow-growing challenge Year: 2007 Antituberculous activity of fiurenizid in vitro and in patients with destructive pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 724s Year: 2004 Method of treatment of destructive tuberculosis of single lung with extensively drug resistant mycobacteria tuberculosis Source: Annual Congress 2011 - Extrapulmonary tuberculosis and surgical interventions Year: 2011 Clinical relevance of Mycobacterium simiae in pulmonary samples Source: Eur Respir J 2008; 31: 106-109 Year: 2008 Non-tuberculous mycobacterial pulmonary disease Source: Eur Respir J, 54 (1) 1900250; 10.1183/13993003.00250-2019 Year: 2019 Outcomes of patients undergoing treatment for non-tuberculous mycobacteria lung disease Source: International Congress 2019 – Clinical investigations of non-TB mycobacterial infection Year: 2019